Comparison of Topical Metronidazole, Ciprofloxacin, Cimetidine, and Meloxicam Treatment in Plaque- Induced Gingivitis

doi:10.17656/sdj.10059

	Comparison of Topical Metronidazole, Ciprofloxacin, Cimetidine, and Meloxicam Treatment in Plaque- Induced Gingivitis
Sulaimani Dental Journal
Article 9, Volume 3, Issue 1, 2016, Pages 58-68 PDF (393.42 K)
DOI: 10.17656/sdj.10059
Abstract
Objectives: The aim of the present study was to evaluate and compare the clinical effectiveness of newly prepared topical dosage forms as an adjunct to scaling and polishing (S & P) in plaque-induced gingivitis. Materials and Methods: The study was conducted on 75 patients (35 males and 40 females) with a moderate to severe gingivitis randomly divided into five groups, each including 15 patients. In each group, the patients received (S & P) plus one of the oral gels (1% metronidazole, 1% ciprofloxacin, 1% cimetidine, 0.5% meloxicam) twice daily for seven days, except group 0 which were treated by (S & P) alone without any drug application. All the patients were evaluated before treatment and 7 days after treatment for plaque index [PLI], gingival index [GI], and bleeding on probing [BOP] and biochemical parameters (salivary enzymes) like aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), and lactate dehydrogenase (LDH). Results: There was a significant improvement following all treatments type when compared to pretreatment records with minor differences in the effects of treatment modalities on the clinical parameters (PLI, GI, and BOP). Combination therapy of (S & P) plus ciprofloxacin gel resulted in the best improvement of PLI and BOP whereas the highest significant improvement in GI was with the combination therapy of (S & P) plus cimetidine gel. Similarly, AST, ALT, CK, and LDH significantly reduced in all five groups, with the most observed reduction of both AST and CK was found in the combination therapy of metronidazole gel along with (S & P). The highest decrease in ALT and LDH was observed with the combination therapy of cimetidine gel along with (S & P). Conclusion: The above studies revealed that adjunctive use of topical gels particularly ciprofloxacin and cimetidine along with (S & P) results in significant benefits in the treatment of plaque-associated gingivitis.
Keywords
oral gel; Metronidazole; Ciprofloxacin; Cimetidine; Meloxicam; gingivitis; and dental plaque

References
1. Kinane DF. Causation and pathogenesis of periodontal disease. Periodontol 2000.2001;25(1):8–20. 2. Newman MG, Takei HH, Klokkevold PR, Carranza FA. Carranza’s Clinical Periodontology 11th Ed 2012. 3. Loe H, Theilade E, Jensen SB. Experimental Gingivitis in Man. J Periodontol. 1966;36:177–87. 4. Treatment of plaque-induced gingivitis, chronic periodontitis, and other clinical conditions. Pediatr Dent. 2005;27(7 Suppl):202-11. 5. Deshpande RG, Khan M, Genco CA. Invasion strategies of the oral pathogen porphyromonas gingivalis: implications for cardiovascular disease. Invasion Metastasis .1999;18(2):57–69. 6. Asikainen S, Chen C. Oral ecology and person-toperson transmission of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Periodontol 2000. 1999;20:65–81. 7. Goodson JM. Antimicrobial strategies for treatment of periodontal diseases. Periodontol 2000. 1994 Jun;5:142–68. 8. Loesche WJ, Grossman N, Giordano J. Metronidazole in periodontitis (IV). The effect of patient compliance on treatment parameters. J Clin Periodontol. 1993;20(2):96–104. 9. Rams TE, Slots J. Local delivery of antimicrobial agents in the periodontal pocket. Periodontol 2000 .1996;10(1):139–59. 10. Silness J, Loe H. Periodontal Disease In Pregnancy. Correlation Between Oral Hygiene And Periodontal Condition. Acta Odontol Scand. 1964;22:121–35. 11. Biolab ALT GPT (IFCC). 80027 AT ALT TGP IFCC. Available from: http://www.biolabo.fr/biolabo/pdfs/noticesE/biochim ieE/80027 AT ALT TGP IFCC. 12. Karmen A, Wroblewski F, Ladue JS. Transaminase activity in human blood. J Clin Invest .1955 ;34(1):126–31. 13. Diagnostics PTZ. EU Represent JTC Diagnosem UG, Schulweg 8, D-34516 Voehl/Germany IFU-LDH-Rev .Available from: Web: www.pishtazteb.com 14. Creatine Kinase - Roche, http://custombiotech.roche.com/content/dam/interne t/dia/custombiotech/ 15. Soskolne WA, Heasman PA, Stabholz A, Smart GJ, Palmer M, Flashner M, et al. Sustained Local Delivery of Chlorhexidine in the Treatment of Periodontitis: A Multi-Center Study. J Periodontol.1997;86(1):32-38 16. John A, Frank J, Bart J, Angelo Mariotti. Pharmacology and Therapeutics for Dentistry, 6th Edition. Elsevier Mosby USA; 2010. p 349, 636, 642. 17. Raghavendra N G, Purushotham K, Muthalik S SA. Clinical studies and antimicrobial activity of ciprofloxacin hydrochloride medicated dental gels for periodontal infection . Asian J PharmA. 2009;3(2): 125–34. 18. Hasturk H, Kantarci A, Ebrahimi N, Andry C, Holick M, Jones VL, et al. Topical H2 antagonist prevents periodontitis in a rabbit model. Infect Immun . 2006 ;74(4):2402–14. 19. Stelzel M, Florès-de-Jacoby L. Topical metronidazole application as an adjunct to scaling and root planing. J Clin Periodontol . 2000 ;27(6):447–52. 20. Al-Mubarak SA, Karring T, Ho A. Clinical evaluation of subgingival application of metronidazole 25%, and adjunctive therapy. J Int Acad Periodontol . 2000;2(3):64–70. 21. Drisko CH. Nonsurgical periodontal therapy. Periodontol 2000. 2001;25:77–88. 22. Howell TH. Blocking periodontal disease progression with anti-inflammatory agents. J Periodontol. 1993;64(8):828–33. 23. Nishibori M, Kohka-Takahashi H, Mori S.[Regulation of cytokine production by histamine through H2-receptor stimulation]. Nihon Yakurigaku Zasshi . 2001;118(1):29–35. 24. Awartani FA, Zulqarnain BJ. Comparison of the clinical effects of subgingival application of metronidazole 25% gel and scaling in the treatment of adult periodontitis. Quintessence Int . 1998 ;29(1):41–8. 25. Reddy MS, Palcanis KG, Barnett ML, Haigh S, Charles CH, Jeffcoat MK. Efficacy of meclofenamate sodium (Meclomen®) in the treatment of rapidly progressive periodontitis. J Clin Periodontol . 1993;20(9):635–40. 26. Cercek JF, Kiger RD, Garrett S, Egelberg J. Relative effects of plaque control and instrumentation on the clinical parameters of human periodontal disease. J Clin Periodontol . 1983 ;10(1):46–56. 27. Vinholis AH, Figueiredo LC, Marcantonio Júnior E, Marcantonio RA, Salvador SL, Goissis G. Subgingival utilization of a 1% chlorhexidine collagen gel for the treatment of periodontal pockets. A clinical and microbiological study. Braz Dent J . 2001;12(3):209–13. 28. Todorovic T, Dozic I, Vicente Barrero M, Ljuskovic B, Pejovic J, Marjanovic M, et al. Salivary enzymes and periodontal disease. Med Oral Patol Oral Cir Bucal. 2006;11:115–9. 29. Ralph ED. Clinical pharmacokinetics of metronidazole. Clin Pharmacokinetics 1983;8(1):43–62. 30. Miyachi Y, Imamura S, Niwa Y. Anti-oxidant action of metronidazole: a possible mechanism of action in rosacea. Br J Dermatol . 1986;114(2):231–4. 31. Chan L, Dyke TE Van, Stahl GL, Merched A, Petasis NA, Kantarci A, et al. Anti-inflammatory Lipid Mediators 15-Lipoxygenase and Endogenous Transgenic Rabbits Overexpressing Reduced Inflammation and Tissue Damage in. J Immunol Ref J Immunol . 2016;171:6856–65.
Statistics Article View: 12 PDF Download: 41